admin

SAN FRANCISCO and TEL AVIV, Israel, Sept. 20, 2018 (GLOBE NEWSWIRE) — Kalytera Therapeutics, Inc. (TSX VENTURE: KALY and OTCQB: KALTF) (the “Company” or “Kalytera“) today provided an update on its lead product development program evaluating cannabidiol (“CBD”) for the prevention and treatment of acute graft versus host disease (“GVHD”). GVHD is a life-threatening complication […]

by

A collaboration between a Canadian supplier of medical cannabis and a biopharma is being touted as a major step towards bringing medical cannabis to patients across the globe. × Building on an existing alliance, Tilray Canada and Sandoz – a Novartis subsidiary – will now work together to increase the availability of medical cannabis products […]

by

RECORDATI AND HELSINN AGREEMENT FOR THE EXCLUSIVE COMMERCIALIZATION RIGHTS TO LEDAGA® Milan and Lugano, December 20, 2018 – Recordati and Helsinn announce the signing of a license agreement between Orphan Europe, a Recordati group company dedicated to providing treatment for patients with unmet medical needs suffering from rare diseases, and Helsinn, a Swiss pharmaceutical group […]

by

Novartis’ Sandoz subsidiary has taken its first steps into the emerging market for medical cannabis products, signing a global supply deal with Canadian producer Tilray. Tilray was the first cannabis company to get a public listing on the Nasdaq early this year, and in the last months has seen its shares rocket from $17 at […]

by

COPENHAGEN, Denmark, Dec. 21, 2018 (GLOBE NEWSWIRE) — Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technology to address significant unmet medical needs, today announced that the company will participate in an upcoming investor conference. Company executives will provide a business overview and update on the company’s pipeline programs. Details […]

by

GENFIT: Positive 30-month DSMB Recommendation for Continuation of Phase 3 RESOLVE-IT Study of Elafibranor in NASH Data Safety Monitoring Board (DSMB) recommended the continuation of  RESOLVE-IT without any modifications, based on the pre-planned review of safety data, including adverse events and laboratory data Positive recommendation consistent with previous observations supporting the favorable safety profile of […]

by

Analysts expect GW Pharmaceuticals plc (NASDAQ:GWPH) to report $-2.99 EPS on February, 4.They anticipate $0.56 EPS change or 23.05% from last quarter’s $-2.43 EPS. After having $-2.76 EPS previously, GW Pharmaceuticals plc’s analysts see 8.33% EPS growth. The stock increased 0.85% or $1.15 during the last trading session, reaching $135.65. About 28,512 shares traded. GW […]

by

The cannabidiol marketplace is likely to witness significant RD investment in the pharmaceutical industry as a broad-spectrum pharmaceutical therapeutics. Multiple scientific studies have shown promising results of cannabidiol for its potential in the treatment of a number of diseases. Following which the cannabidiol market is marked by a considerable cannabidiol therapeutics getting FDA approval or […]

by

Cannabis-based experimental therapies currently under research, in particular Epidiolex, show significant promise to treat therapy-resistant epilepsy, including Dravet syndrome, according to a recent review. The report “Investigational cannabinoids in seizure disorders, what have we learned thus far?” published in the journal Expert Opinion in Investigational Drugs, provides an overview on the recent advances of investigational cannabinoids (cannabis-derived […]

by

Recent studies at Colorado State University’s James L. Voss Veterinary Teaching Hospital, overseen by Dr. Stephanie McGrath, have found the use of cannabidiol to be beneficial for dogs with epilepsy. Atticus, a 3-year old St. Bernard, is enrolled in a CBD oil clinical trial at the James L. Voss Veterinary Teaching Hospital. Atticus is in […]

by